DelveInsight’s “Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hyperphosphatemia, historical and forecasted epidemiology as well as the Hyperphosphatemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Hyperphosphatemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hyperphosphatemia Market Forecast
Some of the key facts of the Hyperphosphatemia Market Report:
The Hyperphosphatemia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In September 2024, Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company focused on kidney disease treatments, announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Oxylanthanum Carbonate (OLC). The application seeks approval for OLC as a treatment for hyperphosphatemia in patients with chronic kidney disease (CKD) undergoing dialysis. The company is pursuing FDA approval through the 505(b)(2) regulatory pathway.
In 2023, the United States recorded the highest prevalence of Hyperphosphatemia in the 7MM, with approximately 500,000 cases.
In 2023, Germany had the highest prevalence of cases among the EU4 countries and the UK, with approximately 56,000 cases.
Japan reported the second-highest prevalence among the 7MM in 2023, with approximately 300,000 cases.
According to DelveInsight’s estimates, the United States had approximately 2.4 million prevalent cases of CKD stages 3–5 in 2023.
The United States had the largest market size for Hyperphosphatemia in the 7MM, estimated at around USD 2,400 million.
In 2023, Germany made the largest market size contribution among the EU4 countries and the UK, totaling approximately USD 150 million.
Key Hyperphosphatemia Companies: FRESENIUS MEDICAL CARE RENAL PHARMACEUTICALS, Astellas pharma, Unicycive Therapeutics, Ardelyx, Shield Therapeutics, Kyowa Kirin Co., Ltd., Shanghai Alebund Pharma, Sanofi, Bayer, Keryx Biopharma, Kissei Pharma, Taisho Pharma, Alebund Pharmaceuticals, Nabi Biopharma, Astellas Pharma Inc, Novartis, Sanofi, Mitsubishi Tanabe Pharma, and others
Key Hyperphosphatemia Therapies: VELPHORO/P-TAL, KIKLIN, Oxylanthanum Carbonate (OLC), Ibsrela (tenapanor), PT20, KHK7791, Tenapanor, VS-505, Sevelamer Carbonate (GZ419831), Lanthanum Carbonate (BAY77-1931), Ferric Citrate, PA21, TS-172, AP-306, calcium acetate, ASP1585, SBR759A, Renvela®, MCI-196, and others
The Hyperphosphatemia epidemiology based on gender analyzed that Hyperphosphatemia occurs in both men and women
The Hyperphosphatemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hyperphosphatemia pipeline products will significantly revolutionize the Hyperphosphatemia market dynamics.
Hyperphosphatemia Overview
A rise in serum phosphate levels exceeding 4.5 mg/100 mL indicates the presence of hyperphosphatemia. In individuals with chronic kidney disease (CKD), the illness is typically brought on by a decline in renal function, which causes phosphate levels to rise unusually high.
Get a Free sample for the Hyperphosphatemia Market Report
https://www.delveinsight.com/report-store/hyperphosphatemia-market
Hyperphosphatemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hyperphosphatemia Epidemiology Segmentation:
The Hyperphosphatemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Hyperphosphatemia
Prevalent Cases of Hyperphosphatemia by severity
Gender-specific Prevalence of Hyperphosphatemia
Diagnosed Cases of Episodic and Chronic Hyperphosphatemia
Download the report to understand which factors are driving Hyperphosphatemia epidemiology trends @ Hyperphosphatemia Epidemiology Forecast
Hyperphosphatemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hyperphosphatemia market or expected to get launched during the study period. The analysis covers Hyperphosphatemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hyperphosphatemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Hyperphosphatemia Therapies and Key Companies
VELPHORO/P-TAL: FRESENIUS MEDICAL CARE RENAL PHARMACEUTICALS
KIKLIN: Astellas pharma
Oxylanthanum Carbonate (OLC): Unicycive Therapeutics
Ibsrela (tenapanor): Ardelyx
PT20: Shield Therapeutics
KHK7791: Kyowa Kirin Co., Ltd.
Tenapanor: Ardelyx
VS-505: Shanghai Alebund Pharma
Sevelamer Carbonate (GZ419831): Sanofi
Lanthanum Carbonate (BAY77-1931): Bayer
Ferric Citrate: Keryx Biopharma
PA21: Kissei Pharma
TS-172: Taisho Pharma
AP-306: Alebund Pharmaceuticals
calcium acetate: Nabi Biopharmaceuticals
ASP1585: Astellas Pharma Inc
SBR759A: Novartis
Renvela®: Sanofi
MCI-196: Mitsubishi Tanabe Pharma
Discover more about therapies set to grab major Hyperphosphatemia market share @ Hyperphosphatemia Treatment Market
Hyperphosphatemia Market Drivers
Promising pipeline activity with newer mechanism of actions
Upsurging research and development
Large target population
Hyperphosphatemia Market Barriers
Poor knowledge of phosphate levels in food and phosphate management
High economic burden
Gastrointestinal side effects
High market competition
Lack of epidemiology data
Scope of the Hyperphosphatemia Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Hyperphosphatemia Companies: FRESENIUS MEDICAL CARE RENAL PHARMACEUTICALS, Astellas pharma, Unicycive Therapeutics, VELPHORO/P-TAL, KIKLIN, Oxylanthanum Carbonate (OLC), Ardelyx, Shield Therapeutics, Kyowa Kirin Co., Ltd., Shanghai Alebund Pharma, Sanofi, Bayer, Keryx Biopharma, Kissei Pharma, Taisho Pharma, Alebund Pharmaceuticals, Nabi Biopharma, Astellas Pharma Inc, Novartis, Sanofi, Mitsubishi Tanabe Pharma, and others
Hyperphosphatemia Therapeutic Assessment: Hyperphosphatemia current marketed and Hyperphosphatemia emerging therapies
Hyperphosphatemia Market Dynamics: Hyperphosphatemia market drivers and Hyperphosphatemia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Hyperphosphatemia Unmet Needs, KOL’s views, Analyst’s views, Hyperphosphatemia Market Access and Reimbursement
To know more about Hyperphosphatemia companies working in the treatment market, visit @ Hyperphosphatemia Clinical Trials and Therapeutic Assessment
Table of Contents
1. Hyperphosphatemia Market Report Introduction
2. Executive Summary for Hyperphosphatemia
3. SWOT analysis of Hyperphosphatemia
4. Hyperphosphatemia Patient Share (%) Overview at a Glance
5. Hyperphosphatemia Market Overview at a Glance
6. Hyperphosphatemia Disease Background and Overview
7. Hyperphosphatemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Hyperphosphatemia
9. Hyperphosphatemia Current Treatment and Medical Practices
10. Hyperphosphatemia Unmet Needs
11. Hyperphosphatemia Emerging Therapies
12. Hyperphosphatemia Market Outlook
13. Country-Wise Hyperphosphatemia Market Analysis (2020–2034)
14. Hyperphosphatemia Market Access and Reimbursement of Therapies
15. Hyperphosphatemia Market Drivers
16. Hyperphosphatemia Market Barriers
17. Hyperphosphatemia Appendix
18. Hyperphosphatemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
